CYP 1.89% 27.0¢ cynata therapeutics limited

Ann: Strategic Review of Cynata Clinical Development Portfolio, page-14

  1. 3,875 Posts.
    lightbulb Created with Sketch. 1314
    You are more game than I.
    The old had problems, the new still has the same problems. They just dont go away.
    CYP is only getting in line if MSB fail to get approval.

    The trial that CYP has put forward is a very good indication that they know they would not be able to match effecacy to MSB .
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
27.0¢
Change
0.005(1.89%)
Mkt cap ! $48.50M
Open High Low Value Volume
27.0¢ 27.0¢ 27.0¢ $4 13

Buyers (Bids)

No. Vol. Price($)
1 18895 26.5¢
 

Sellers (Offers)

Price($) Vol. No.
28.5¢ 5700 1
View Market Depth
Last trade - 13.43pm 05/07/2024 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.